Deferiprone-Induced Agranulocytosis
- 1 June 1997
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 13 (6) , 345-349
- https://doi.org/10.2165/00044011-199713060-00007
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Deferiprone‐associated myelotoxicityEuropean Journal of Haematology, 1994
- The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture systemBritish Journal of Haematology, 1994
- Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitroEuropean Journal of Haematology, 1994
- Agranulocytosis in a Patient with Thalassaemia major during Treatment with the Oral Iron Chelator, 1,2-Dimethyl-3-Hydroxypyrid-4-0neActa Haematologica, 1993
- Metabolism of Clozapine† by NeutrophilsDrug Safety, 1992
- Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis.1991
- AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIALThe Lancet, 1989
- Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studiesPsychopharmacology, 1989
- Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytesChemical Research in Toxicology, 1988